胸腺基质淋巴细胞生成素
先天性淋巴细胞
特应性皮炎
白细胞介素33
免疫学
细胞因子
丝状蛋白
医学
过敏性接触性皮炎
白细胞介素
过敏
免疫系统
先天免疫系统
标识
DOI:10.1016/j.jdermsci.2019.08.006
摘要
Atopic dermatitis (AD) is characterized by pruritus, barrier disruption, and inflammationincluding type 2 cytokine production. Interleukin-33 (IL-33) is an inflammatory cytokine that is over-expressed in the keratinocytes of patients with AD. IL-33 transgenic mice, which express IL-33 specifically in keratinocytes, spontaneously develop AD-like eczema, suggesting that IL-33 is sufficient for the development of AD. IL-33 stimulates various cells, including group 2 innate lymphoid cells (ILC2s), to produce type 2 cytokines, such as IL-5 and IL-13, and IL-33-stimulated basophils activate ILC2s via IL-4. ILC2s are enriched in human AD skin lesions, and ILC2 isolated from AD lesions, are activated by IL-33, not by thymic stromal lymphopoietin (TSLP). IL-33 induces IL-31, thereby promoting pruritus and scratching behavior. Conversely, scratching the skin promotes IL-33 release from keratinocytes. IL-33 reduces the expression of filaggrin and claudin-1; it also reduces the skin barrier function. However, barrier destruction causes percutaneous exposure to allergens or IL-33 release. Thus, IL-33 is a common point of entry into the itch–scratch cycle of AD. These new findings can facilitate the development of novel therapeutic drugs targeting IL-33.
科研通智能强力驱动
Strongly Powered by AbleSci AI